Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06246461
Other study ID # JJPH-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date January 22, 2024

Study information

Verified date January 2024
Source Jingjiang People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.Different administration regimens of capecitabine were given, and the treatment course was appropriately extended. The therapeutic effect and incidence of adverse reactions were observed.


Description:

To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group. Afterward, the response rate, quality of life, and adverse reactions of the three groups were collected for comparison.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date January 22, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 69 Years
Eligibility Inclusion Criteria: - According to the diagnostic criteria for colon cancer in the Consensus on Screening, Diagnosis and Treatment of Early Colorectal Cancer and Precancerous Lesions in China , colon cancer was confirmed by pathology - TNM(tumor node metastasis) clinical stage was III or IV - Predicted survival period > 3 months Exclusion Criteria: - Patients with heart, liver, kidney and other important organ failure and contraindications to chemotherapy - Patients who received other anti-tumor therapy before admission - The disease progressed rapidly and could not be successfully completed by this researcher - Allergic to related drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
capecitabine
The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.

Locations

Country Name City State
China Clinical effect analysis of different regimens of capecitabine in the treatment of patients with advanced colon cancer Jingjiang Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jingjiang People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical efficacy:Overall response rate(RR%) Overall response rate (RR%): complete response (CR) + partial response (PR)/total number of cases×100%. After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days)
Primary Clinical efficacy:Disease control rate(DR)% Disease control rate (DR)% = (CR+PR+SD)/total number of cases×100%. After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days)
Primary Quality of life:QLQ-C30(Quality of Life Questionnaire-core30) Score Quality of life was scored using the QLQ-C30 (Quality of Life Questionnaire-core30).QLQ-C30 is composed of one global quality of life scale and five functional scales, which include physical function, role function, emotional function, cognitive function, and social function. Scoring criteria: After the scores of each part of the scale were converted to standardized scores, the scores ranged from 0 to 100, and the higher the score of the scale, the better the overall quality of life and functional status. After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days)
Primary Incidence of adverse reactions Adverse reactions include hand-foot syndrome, stomatitis, leukopenia, nausea and vomiting, bone marrow suppression, and pigmentation. Incidence of adverse reactions%=number of adverse reaction cases/total number of cases × 100% After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days)
See also
  Status Clinical Trial Phase
Completed NCT03079440 - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Phase 2
Completed NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT05290194 - Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Recruiting NCT06169202 - A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Not yet recruiting NCT05841134 - Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Phase 2
Recruiting NCT05970302 - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Phase 2
Recruiting NCT05022030 - First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes Phase 2
Recruiting NCT06202014 - Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC Phase 2
Enrolling by invitation NCT03030508 - Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients N/A
Recruiting NCT02012634 - Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Phase 3
Active, not recruiting NCT06188000 - Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine N/A
Completed NCT04720131 - Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. Phase 2
Active, not recruiting NCT03258099 - Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05535413 - UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Active, not recruiting NCT03500380 - A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases Phase 2/Phase 3
Recruiting NCT06405490 - NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Phase 2